Diagnòstic Hematològic

Bussaglia E., Anton R., Nomdedeu J.F., Fuentes-Prior P. (2019) TET2 missense variants in human neoplasia. A proposal of structural and functional classification. MOL GENET GENOM MED, 7 (7), -.
IF: 1,9950

de la Guardia R.D., Lopez-Millan B., Roca-Ho H., Bueno C., Gutierrez-Aguera F., Fuster J.L., Anguita E., Zanetti S.R., Vives S., Nomdedeu J., Sackstein R., Lavoie J., Gonzalez-Rey E., Delgado M., Rosu-Myles M., Menendez P. (2019) Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis. HAEMATOLOGICA, 104 (2), e54-e58.
IF: 7,1160

Monter A., Nomdedeu J.F. (2019) ClonoSEQ assay for the detection of lymphoid malignancies. EXPERT REV MOL DIAGN, 19 (7), 571-578.
IF: 4,0960

Mora A., Bosch R., Cuellar C., Vicente E.P., Blanco L., Martino R., Ubeda J.M., Sierra J., Moreno C., Nomdedeu J. (2019) CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. CYTOM PART B-CLIN CY, 96 (2), 143-148.
IF: 2,0700

Onecha E., Linares M., Rapado I., Ruiz-Heredia Y., Martinez-Sanchez P., Cedena T., Pratcorona M., Oteyza J.P., Herrera P., Barragan E., Montesinos P., Vela J.A.G., Magro E., Anguita E., Figuera A., Riaza R., Martinez-Barranco P., Sanchez-Vega B., Nomdedeu J., Gallardo M., Martinez-Lopez J., Ayala R. (2019) A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. HAEMATOLOGICA, 104 (2), 288-296.
IF: 7,1160

Ribera J., Granada I., Morgades M., Vives S., Genesca E., Gonzalez C., Nomdedeu J., Escoda L., Montesinos P., Mercadal S., Coll R., Gonzalez-Campos J., Abella E., Barba P., Bermudez A., Gil C., Tormo M., Pedreno M., Martinez-Carballeira D., Hernandez-Rivas J.-M., Orfao A., Martinez-Lopez J., Esteve J., Bravo P., Garcia-Guinon A., Deben G., Moraleda J.M., Quiezan J.A., Ortin X., Moreno M.J., Feliu E., Sole F., Ribera J.M. (2019) The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. BRIT J HAEMATOL, 186 (2), 263-268.
IF: 5,5180

Ribera J., Zamora L., Morgades M., Vives S., Granada I., Montesinos P., Gomez-Segui I., Mercadal S., Guardia R., Nomdedeu J., Pratcorona M., Tormo M., Martinez-Lopez J., Hernandez-Rivas J.-M., Ciudad J., Orfao A., Gonzalez-Campos J., Barba P., Escoda L., Esteve J., Genesca E., Sole F., Feliu E., Ribera J.-M. (2019) Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. GENE CHROMOSOME CANC, 58 (11), 815-819.
IF: 3,4440

Santaliestra M., Garrido A., Carricondo M., Bussaglia E., Pratcorona M., Blanco M.L., Gich I., Hoyos M., Esquirol A., Garcia-Cadenas I., Brunet S., Martino R., Sierra J., Nomdedeu J.F. (2019) Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. EUR J HAEMATOL, 103 (3), 208-214.
IF: 2,2200

Sobas M., Montesinos P., Boluda B., Bernal T., Vellenga E., Nomdedeu J., Gonzalez-Campos J., Chillon M., Holowiecka A., Esteve J., Bergua J., Gonzalez-Sanmiguel J.D., Gil-Cortes C., Tormo M., Salamero O., Manso F., Fernandez I., de la Serna J., Moreno M.-J., Perez-Encinas M., Krsnik I., Ribera J.-M., Escoda L., Lowenberg B., Sanz M.A. (2019) An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. LEUKEMIA LYMPHOMA, 60 (4), 1030-1035.
IF: 2,9690

Genesca E., Lazarenkov A., Morgades M., Berbis G., Ruiz-Xiville N., Gomez-Marzo P., Ribera J., Junca J., Gonzalez-Perez A., Mercadal S., Guardia R., Artola M.T., Moreno M.J., Martinez-Lopez J., Zamora L., Barba P., Gil C., Tormo M., Cladera A., Novo A., Pratcorona M., Nomdedeu J., Gonzalez-Campos J., Almeida M., Cervera J., Montesinos P., Batlle M., Vives S., Esteve J., Feliu E., Sole F., Orfao A., Ribera J.M. (2018) Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J HEMATOL ONCOL, 11 (1), -.
IF: 8,7310

Guillem V., Calabuig M., Brunet S., Esteve J., Escoda L., Gallardo D., Ribera J.-M., Queipo de Llano M.P., Arnan M., Pedro C., Amigo M.L., Marti-Tutusaus J.M., Garcia-Guinon A., Bargay J., Sampol A., Salamero O., Font L., Talarn C., Hoyos M., Diaz-Beya M., Garrido A., Navarro B., Nomdedeu J., Sierra J., Tormo M. (2018) Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. LEUKEMIA LYMPHOMA, 59 (10), 2383-2393.
IF: 2,6740

Martinez-Pedrero F., Tajuelo J., Sanchez-Puga P., Chulia-Jordan R., Ortega F., Rubio M.A., Rubio R.G. (2018) Linear shear rheological of aging β-casein films adsorbing at the air/water interface. J COLLOID INTERF SCI, 511 (), 12-20.
IF: 6,3610

Nomdedeu J.F., Esquirol A., Carricondo M., Pratcorona M., Hoyos M., Garrido A., Rubio M., Bussaglia E., Garcia-Cadenas I., Estivill C., Brunet S., Martino R., Sierra J. (2018) Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value. BIOL BLOOD MARROW TR, 24 (1), 55-63.
IF: 3,5990

Pallares V., Hoyos M., Chillon M.C., Barragan E., Conde M.I.P., Llop M., Falgas A., Cespedes M.V., Montesinos P., Nomdedeu J.F., Brunet S., Sanz M.A., Gonzalez-Diaz M., Sierra J., Mangues R., Casanova I. (2018) Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia. CANCERS, 10 (11), -.
IF: 6,1620

Rawstron A.C., Kreuzer K.-A., Soosapilla A., Spacek M., Stehlikova O., Gambell P., Mciver-Brown N., Villamor N., Psarra K., Arroz M., Milani R., de la Serna J., Cedena M.T., Jaksic O., Nomdedeu J., Moreno C., Rigolin G.M., Cuneo A., Johansen P., Johnsen H.E., Rosenquist R., Niemann C.U., Kern W., Westerman D., Trneny M., Mulligan S., Doubek M., Pospisilova S., Hillmen P., Oscier D., Hallek M., Ghia P., Montserrat E. (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. CYTOM PART B-CLIN CY, 94 (1), 121-128.
IF: 2,9380

Torrebadell M., Diaz-Beya M., Kalko S.G., Pratcorona M., Nomdedeu J., Navarro A., Gel B., Brunet S., Sierra J., Camos M., Esteve J. (2018) A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. LEUKEMIA LYMPHOMA, 59 (10), 2394-2404.
IF: 2,6740

Vazquez-Santiago M., Vilalta N., Cuevas B., Murillo J., Llobet D., Macho R., Pujol-Moix N., Carrasco M., Mateo J., Fontcuberta J., Soria J.M., Souto J.C. (2018) Short closure time values in PFA–100® are related to venous thrombotic risk. Results from the RETROVE Study. THROMB RES, 169 (), 57-63.
IF: 3,2660

Vicente E.P., Cuellar-Garcia C., Martinez M., Soler A., Mora A., Bosch R., Brunet S., Briones J., Garcia I., Esquirol A., Granell M., Saavedra S., Nomdedeu J., Sierra J., Martino R., Moreno C. (2018) Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. CL LYMPH MYELOM LEUK, 18 (11), 737-742.
IF: 2,2740